Monomeric M2e antigen in VesiVax^® liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e

References

• Adler-Moore, J., et al., 2011. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine, 29 (27), 4460–4468.
   PubMed Web of Science ®Google Scholar
• Andersson, A.M.C., et al., 2012. Increased immunogenicity and protective efficacy of Influenza M2e fused to a Ttetramerizing protein. PLoS one, 7 (10), e46395.
   PubMed Web of Science ®Google Scholar
• Black, R.A., et al., 1993. Antibody response to the M2 protein of influenza A virus expressed in insect cells. Journal of general virology, 74 (Pt1), 143–146.
   Web of Science ®Google Scholar
• Bouvier, N.M. and Lowen, A.C., 2010. Animal models for Influenza virus pathogenesis and transmission. Viruses, 2 (8), 1530–1563.
   PubMed Web of Science ®Google Scholar
• Cho, K.J., et al., 2016. Crystal structure of the conserved amino terminus of the extracellular domain of Matrix Protein 2 of Influenza A virus gripped by an antibody. Journal of virology, 90, 611–615.
   PubMed Web of Science ®Google Scholar
• De Filette, M., et al., 2008a. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. The journal of biological chemistry, 283 (17), 11382–11387.
   PubMed Web of Science ®Google Scholar
• De Filette, M., et al., 2008b. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine, 26 (51), 6503–6507.
   PubMed Web of Science ®Google Scholar
• De Filette, M., et al., 2011. Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective. Journal of general virology, 92 (2), 301–306.
   PubMed Web of Science ®Google Scholar
• Deng, L., et al., 2015. Protection against influenza A virus challenge with M2e-displaying filamentous Escherichia coli phages. PLoS one, 10 (5), e0126650.
   Google Scholar
• Ebrahimi, S.M. and Tebianian, M., 2010. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70 (359–610) in prokaryotic system as a fusion protein. Molecular biology reports, 37 (6), 2877–2883.
   PubMed Web of Science ®Google Scholar
• Ebrahimi, S.M., et al., 2010. Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris. Protein expression and purification, 70 (1), 7–12.
   PubMed Web of Science ®Google Scholar
• Epstein, S.L., et al., 2002. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerging infectious diseases, 8, 796–801.
   PubMed Web of Science ®Google Scholar
• Ernst, W.A., et al., 2006. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine, 24 (24), 5158–5168.
   PubMed Web of Science ®Google Scholar
• Fiers, W., et al., 2004. A “universal” human influenza A vaccine”. Virus research, 103 (1–2), 173–176.
   PubMed Web of Science ®Google Scholar
• Fiers, W., et al., 2001. Soluble recombinant influenza vaccines. Philosophical transactions of the royal society of London: series B, biological sciences, 356 (1416), 1961–1963.
   PubMed Web of Science ®Google Scholar
• Huleatt, J.W., et al., 2008. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine, 26 (2), 201–214.
   PubMed Web of Science ®Google Scholar
• Ibanez, L.I., et al., 2013. M2e-Displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLoS one, 8 (3), e59081.
   PubMed Web of Science ®Google Scholar
• Jegerlehner, A., et al., 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. Journal of immunology, 172 (9), 5598–5605.
   PubMed Web of Science ®Google Scholar
• Jimenez, G.S., et al., 2007. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Human vaccines, 3 (5), 157–164.
   PubMed Web of Science ®Google Scholar
• Liu, W., Li, H., and Chen, Y.H., 2003. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS immunology and medical microbiology, 35 (2), 141–146.
   PubMedGoogle Scholar
• Liu, W., et al., 2005. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes and infection, 7 (2), 171–177.
   PubMed Web of Science ®Google Scholar
• Margine, I. and Krammer, F., 2014. Animal models for Influenza viruses: implications for universal vaccine development. Pathogens (Basel, Switzerland), 3 (4), 845–874.
   PubMedGoogle Scholar
• Mozdzanowska, K., et al., 2003. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine, 21 (19–20), 2616–2626.
   PubMed Web of Science ®Google Scholar
• Neirynck, S., et al., 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature medicine, 5 (10), 1157–1163.
   PubMed Web of Science ®Google Scholar
• Okuda, K.K., et al., 2001. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine, 19 (27), 3681–3691.
   PubMed Web of Science ®Google Scholar
• Slepushkin, V.A., et al., 1995. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine, 13 (15), 1399–1402.
   PubMed Web of Science ®Google Scholar
• Tao, W., et al., 2017. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. Antiviral research, 141, 62–72.
   PubMed Web of Science ®Google Scholar
• Tompkins, S.M., et al., 2007. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases, 13, 426–435.
   PubMed Web of Science ®Google Scholar
• Treanor, J.J., et al., 1990. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. Journal of virology, 64 (3), 1375–1377.
   PubMed Web of Science ®Google Scholar
• Wang, R., et al., 2008. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral research, 80 (2), 168–177.
   PubMed Web of Science ®Google Scholar
• Watabe, S., et al., 2001. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine, 19, 4434–4444.
   PubMed Web of Science ®Google Scholar
• Zebedee, S.L. and Lamb, R.A., 1988. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Journal of virology, 62, 2762–2772.
   PubMed Web of Science ®Google Scholar